Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Oncolytics Biotech Inc. (Nasdaq: ONCY) Just Landed At The Top Of The Krypton Street Watchlist This Morning—Tuesday, October 13 2026… Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Take A Close Look At (ONCY) While It’s Still Early… October 13, 2026 Dear Reader, Three FDA Fast Track designations, written registrational alignment, clinical data showing 2-3x improvements over standard of care — and now RSI readings on Barchart sitting at 13.28 on the 9-day, 18.41 on the 14-day, and 23.71 on the 20-day. All three below 30… The threshold some technical frameworks tie to what’s commonly called “oversold territory” — the kind of zone that could indicate a potential trend reversal is in the works. Oncolytics Biotech Inc. (Nasdaq: ONCY) is developing pelareorep, a first-in-class double-stranded RNA immunotherapy that works through a dual mechanism — selectively replicating inside tumor cells while simultaneously activating both innate and adaptive immune responses, converting immunologically “cold” tumors to “hot.” The company has been building directly into one of oncology’s widest gaps. Gastrointestinal cancers are the fastest-growing cancer category among adults under 50 worldwide, and the three subtypes pelareorep targets carry some of the most severe unmet needs — roughly 1.9M new colorectal cancer diagnoses globally each year, a five-year metastatic survival rate of just 3% in pancreatic cancer, and zero FDA-approved options for advanced anal cancer patients who progress after front-line therapy. The FDA has provided written alignment on a registrational path forward in second-line colorectal cancer… And with technical readings sitting where they are right now, this is a name that deserves your full attention. Do not sleep on (ONCY) this morning—Tuesday, October 13, 2026. 
And as of right now, three analysts currently cover (ONCY)… Jason McCarthy of Maxim Group carries a $3 target, while Patrick Trucchio of H.C. Wainwright and Chad Messer of Lake Street each carry $5 targets — suggesting more than 500% upside from the recent $.50 range. Clinical Data Across Three GI Cancer Programs The efficacy data from pelareorep's three lead programs reflects a consistent and substantial separation from established benchmarks across each indication. In second-line KRAS-mutant metastatic colorectal cancer, the REO 022 study delivered progression-free survival of 16.6 months versus 5.7 months, overall survival of 27 months versus 11.2 months, an objective response rate of 33% versus 6-11%, and a median duration of response of 19.5 months versus 4-6 months for recently approved targeted therapies — representing 2-3x improvements across nearly every key endpoint in a RAS-mutant population that has historically been among the most difficult to treat. In advanced squamous cell anal carcinoma, the GOBLET study produced a 30% objective response rate — more than double historical benchmarks — with a duration of response of approximately 15.5 months versus 9.5 months and a 12-month overall survival rate of 82% compared to 45.7%. That 82% figure carries additional weight in a setting where no FDA-approved therapies exist following front-line treatment. In first-line metastatic pancreatic ductal adenocarcinoma, pelareorep-based therapy demonstrated a 2-year survival rate of approximately 22% versus roughly 9.2% across comparator arms from landmark studies — a ~2.5x improvement in an indication where no immunotherapy has been approved and where the standard of care has remained largely unchanged. The compound has been administered to more than 1,200 patients across multiple cancer types, with a pooled safety analysis of over 500 patients showing no maximum tolerated dose and a "generally well-tolerated" profile — supporting its use as a combination agent across multiple tumor types and treatment settings. The FDA Just Agreed to a Path Forward 
You don't always see this from a clinical-stage company… Three Fast Track designations from a single agency in a span of less than four years — and all in the same therapeutic area. Oncolytics Biotech Inc. (Nasdaq: ONCY) now holds three separate Fast Track designations from the FDA — colorectal cancer (February 2026), anal cancer (July 2026), and pancreatic cancer (late 2022). Each one validates the agency's recognition that pelareorep addresses serious diseases with significant unmet medical needs. It also opens the door to more frequent regulatory interactions, rolling review of a future application, and potential Priority Review eligibility — tools that compress timelines and keep momentum moving forward. But here's the part that really stands out… On August 18th, the FDA provided written alignment on a potential pivotal Part B expansion of REO 033 — the company's ongoing controlled study in second-line RAS-mutant MSS metastatic colorectal cancer. That feedback included alignment around using objective response rate to support an accelerated approval pathway… With progression-free survival supporting full approval. "We are thrilled with the response provided by the FDA and believe this feedback could support a highly efficient path to potentially transition REO 033 from its ongoing randomized Part A directly into a pivotal Part B," said Jared Kelly, CEO of Oncolytics Biotech Inc. (Nasdaq: ONCY). REO 033 is currently enrolling patients at 15-20 U.S. sites, with preliminary data expected Q4 2026. Final GOBLET cohort 4 data from the anal cancer program is expected in the second half of 2026, and the company's seeking a partnership to advance toward a pivotal controlled study there. Expanding the Platform Beyond the Lead Programs 
The development scope for pelareorep extends beyond its three lead GI cancer programs, and recent preclinical data has added a new dimension to the compound's combination potential. Last month, Oncolytics Biotech Inc. (Nasdaq: ONCY) announced positive preclinical results combining pelareorep with a pan-RAS inhibitor in a RAS-driven colorectal cancer model, demonstrating maintained pelareorep activity without evidence of antagonism — a finding that carries forward-looking relevance given that acquired resistance remains the primary limitation of RAS-targeted therapies across multiple tumor types. "These results provide an encouraging first look at combining pelareorep with one of the most important emerging classes of targeted cancer therapies," said Thomas Heineman, MD, PhD, Chief Medical Officer. The preclinical pipeline extends beyond RAS inhibitors, with combination programs advancing alongside CAR-T therapies, bispecific antibodies, and antibody-conjugate platforms. From an IP and manufacturing standpoint, 139 patents have been issued worldwide with manufacturing protection to 2044 and method-of-use coverage expected through 2046, while pelareorep's production profile — high yield, low cost-of-goods, no special handling — supports a straightforward path to commercial-scale output across multiple indications. The addressable market reinforces the scale of the commercial case… Colorectal cancer therapeutics represent approximately $20B growing at 4.7% CAGR to 2033, with immunotherapy holding the largest and fastest-growing segment share. The U.S. anal cancer market represents an estimated $1B annual commercial opening with no approved second-line therapies. 
And pancreatic cancer treatment is projected to reach $3B with a 15% CAGR to 2032, per Fortune Business Insights. CEO Jared Kelly brings more than 50 completed transactions to the table, including a $2B acquisition, and CMO Thomas Heineman has nearly 30 years of virology and oncology development experience — a management composition that aligns with a company approaching late-stage development and potential partnership discussions. Combined, pelareorep's three lead GI programs target addressable markets well above $25B — with the company currently valued at under $100M according to Yahoo Finance. 10 Reasons Why We’re Taking A Closer Look At (ONCY) This Morning —Tuesday, October 13, 2026 1. Oversold Territory: RSI readings on Barchart are showing 13.28 on the 9-day, 18.41 on the 14-day, and 23.71 on the 20-day — all below the 30 threshold that some technical frameworks associate with “oversold territory,” a zone some would tie to the setup for a potential trend reversal. 2. Analyst Coverage: three analysts covering ONCY carry targets ranging from $3 to $5, pointing to significant upside potential from the recent $0.50 range. 3. FDA Alignment: in August, ONCY received written FDA alignment on a potential pivotal Part B expansion of REO 033, including use of objective response rate to support a potential accelerated approval pathway. 4. Colorectal Data: in second-line KRAS-mutant metastatic colorectal cancer, ONCY reported 16.6-month progression-free survival versus a 5.7-month benchmark and 27-month overall survival versus 11.2 months. 5. Response Rate: the GOBLET study from ONCY showed a 30% objective response rate and an 82% 12-month overall survival rate versus a 45.7% historical benchmark. 6. Pancreatic Signal: in first-line metastatic pancreatic cancer, ONCY reported an approximately 22% two-year survival rate versus roughly 9.2% across comparator arms from landmark studies. 7. Three Fast Tracks: pelareorep from ONCY holds three separate FDA Fast Track designations covering colorectal, anal, and pancreatic cancer programs. 8. Near-Term Data: REO 033 from ONCY is enrolling at 15-20 U.S. sites with preliminary colorectal cancer data expected in Q4 2026. 9. Patent Position: the intellectual property portfolio behind ONCY includes 139 issued patents worldwide, with manufacturing protection extending to 2044 and method-of-use filings expected through 2046. 10. Market Scale: pelareorep’s three lead GI programs give ONCY exposure to addressable markets totaling more than $25B while the company was listed at a $101M valuation. Take A Close Look At (ONCY) While It’s Still Early… 
The convergence of FDA registrational alignment, three Fast Track designations, and clinical data reflecting 2-3x improvements across three GI cancer indications presents a profile that warrants detailed analytical review — and Oncolytics Biotech Inc. (Nasdaq: ONCY) leads our report heading into tomorrow morning. (ONCY) is the name to review before tomorrow's session. Keep an eye on your inbox and mobile device — our next update could be arriving earlier than usual. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KS is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 10/13/2026 and ending on 10/13/2026 to publicly disseminate information about (ONCY:US) via digital communications. Under this agreement, TD Media LLC has paid Media 1717 LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Media 1717 LLC has been paid thirty seven thousand five hundred USD (“Funds”). These Funds were part of the fifty four thousand USD funds that TD Media LLC received from Oncolytics Biotech Inc., the issuer of (ONCY:US). Neither Media 1717 LLC, TD Media LLC and their member own shares of (ONCY:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/oncy-a1NMK/#details |
